ASP2998 + Pembrolizumab + Enfortumab Vedotin + Carboplatin
Phase 1/2Recruiting 0 views this week 0 watching💤 Quiet
Interest: 39/100
39
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Locally Advanced or Metastatic Malignant Solid Tumors
Conditions
Locally Advanced or Metastatic Malignant Solid Tumors
Trial Timeline
Feb 5, 2026 → Jun 30, 2029
NCT ID
NCT07287995About ASP2998 + Pembrolizumab + Enfortumab Vedotin + Carboplatin
ASP2998 + Pembrolizumab + Enfortumab Vedotin + Carboplatin is a phase 1/2 stage product being developed by Astellas Pharma for Locally Advanced or Metastatic Malignant Solid Tumors. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07287995. Target conditions include Locally Advanced or Metastatic Malignant Solid Tumors.
What happened to similar drugs?
5 of 20 similar drugs in Locally Advanced or Metastatic Malignant Solid Tumors were approved
Approved (5) Terminated (1) Active (14)
Hype Score Breakdown
Clinical
9
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07287995 | Phase 1/2 | Recruiting |
Competing Products
20 competing products in Locally Advanced or Metastatic Malignant Solid Tumors